CUIDAme. Metabolismo y nutrición
University of British Columbia
Vancouver, CanadáPublicaciones en colaboración con investigadores/as de University of British Columbia (10)
2020
-
Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial
Calcified Tissue International, Vol. 106, Núm. 6, pp. 646-654
-
Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial
Osteoporosis International, Vol. 31, Núm. 10, pp. 1935-1942
-
Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use"
Journal of Clinical Endocrinology and Metabolism
-
Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial
Bone, Vol. 130
2019
-
Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis
Bone, Vol. 120, pp. 1-8
-
Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial
Archives of Osteoporosis, Vol. 14, Núm. 1
2018
-
Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial
Journal of Bone and Mineral Research, Vol. 33, Núm. 5, pp. 783-794
-
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
The Lancet, Vol. 391, Núm. 10117, pp. 230-240
-
Teriparatide vs risedronate for osteoporosis – Authors' reply
The Lancet